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 The QuantiFERON  ®  -TB Gold In-Tube test (QFN) measures interferon-gamma production in response to Mycobacterium 
tuberculosis antigens. Our aim was to assess the kinetics of the QFN and initial tuberculin skin test (TST) result in relation 
to severity of disease in a tuberculosis (TB) endemic area. Smear-positive TB patients ( n   71) were recruited at Gondar 
University Hospital, Ethiopia. The TST, QFN, CD4  cell count and clinical symptoms (TB score) were assessed and fol-
lowed up during treatment. From baseline to 7 months after treatment, there was a signifi cant decrease in QFN reactivity 
(93.8% to 62.5% in HIV-negative/TB; 70.3% to 33.3% in HIV-positive/TB patients) down to a level comparable to a 
control group of blood donors (51.2%). The agreement between TST and QFN was poor in TB patients compared to 
healthy controls. A negative TST correlated to more advanced TB in contrast to a negative QFN test. We conclude that 
the QFN reactivity is signifi cantly reduced at the end of treatment against active TB to the background level of healthy 
blood donors, and that the agreement between TST and QFN is poor including correlation to the severity of disease.  Introduction 
 The tuberculin skin test (TST) has been used as a 
diagnostic tool for tuberculosis (TB) since the 19 th 
century and it has a high specifi city in non-BCG 
(bacille Calmette – Gu é rin) vaccinated populations, 
but markedly reduced specifi city in BCG vaccinated 
individuals. Furthermore, the TST is associated with 
low sensitivity in people with impaired cellular immu-
nity and has logistical drawbacks, i.e. patients need 
to return to the healthcare facility for the result to be 
recorded [1]. 
 In recent years, interferon-gamma release assays 
(IGRAs) measuring in vitro T-cell interferon gamma 
(IFN- γ ) production in response to antigens that are 
highly specifi c for Mycobacterium tuberculosis have   Correspondence: J. Idh, Department of Medical Microbiology, Faculty of Hea
703 969897. E-mail: jonna.idh@liu.se 
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DOI: 10.3109/00365548.2010.482942been developed. The IGRAs are not affected by BCG 
vaccination and the specifi city for M. tuberculosis 
infection is high for the 2 commercially available 
IGRAs, QuantiFERON  ®  -TB Gold In-Tube (QFN) 
and T-SPOT.TB. The sensitivity of IGRAs and 
the TST is not consistent across tests and populations, 
but T-SPOT.TB appears to be slightly more sensitive 
than QFN and TST, at least when comparing to active 
TB. The lack of a gold standard for diagnosing latent 
TB complicates the interpretation of such studies, 
since the tests are rarely directly compared [2]. 
 In high endemic countries for TB, IGRA positiv-
ity in the healthy population is reported to be in 
the range of 30% to 60% both in HIV-infected and 
HIV-uninfected individuals, refl ecting an expected lth Sciences, Link ö ping University, SE-581 85 Link ö ping, Sweden. Tel:   46 
iFERON in relation to TST and severity of disease  651
Sc
an
d 
J I
nf
ec
t D
is 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
U
ni
ve
rs
ity
 o
f W
at
er
lo
o 
on
 1
1/
16
/1
4
Fo
r p
er
so
na
l u
se
 o
nl
y.  Quant
high prevalence of latent TB in communities with 
a high level of ongoing transmission [3]. In low 
endemic areas, the IGRAs are useful in distinguish-
ing latent TB infection from a positive TST due to 
BCG vaccination [4]. 
 The limited studies conducted on HIV co-infected 
smear-positive TB patients do not always agree on the 
impact of immune suppression and low CD4  cell 
counts on the sensitivity of the QFN test and possible 
increase in the number of indeterminate results as a 
result of a generally low IFN- γ response [5 – 7]. Fur-
thermore, little is known about the kinetics of QFN 
results during anti-TB treatment in relation to severity 
of the disease in high endemic areas. Available studies 
have shown a moderate reduction in the rate of posi-
tive QFN results following treatment and a correlation 
to increased sputum conversion [8 – 11], but few fol-
low-up studies have investigated the correlation to 
clinical outcome and severity of the disease. Moreover, 
little is known about the reasons and clinical correlates 
of the reported discordance between IGRAs and the 
TST in active TB [12]. A clinical scoring system for 
evaluating severity of disease  – the TB score  – has 
recently been developed and consists of a combination 
of clinical symptoms and signs of TB. This score has 
been validated and can be used to monitor TB patients 
during treatment and to assess clinical outcome and 
severity of disease in a standardized way, as a high TB 
score is associated with an increased mortality [13]. 
 In this study, the aim was to investigate the kinet-
ics of the QFN test during the treatment of patients 
with smear-positive TB in relation to the initial TST 
result and severity of disease. 
 Materials and methods 
 Study subjects and design 
 Consecutive patients with newly diagnosed smear-
positive TB ( n   71) were recruited at the directly 
observed treatment short-course (DOTS) clinic of 
Gondar University Hospital, Ethiopia. The inclusion 
criteria were age 15 – 60 y and acid-fast bacilli (AFB) 
sputum smear-positive TB. The exclusion criteria were 
hospitalization, pregnancy, or concomitant disease 
other than HIV. Smear-positive pulmonary TB was 
defi ned as 2 out of 3 morning sputum samples positive 
for AFB or 1 out of 3 positive with a chest X-ray and 
clinical symptoms suggestive of active pulmonary TB. 
Sputum AFB status was examined by microscopy and 
recorded at baseline, 8 weeks and 7 months after ini-
tiating treatment. Sputum conversion was defi ned as 
3 consecutive sputum smears turning negative for 
AFB. Treatment outcome was recorded for all patients 
at the end of treatment according to the World Health 
Organization guidelines. According to these guidelines, the defi nition of  ‘ cured ’ is a patient who was smear-
positive at the start of treatment, completed treatment 
and who was smear-negative at the end of treatment 
and on 1 previous occasion. A community control 
group of blood donors was recruited at the blood bank, 
Gondar University Hospital. Eligible study subjects 
were interviewed and were not included in the study 
if they had previously been treated for TB or had a 
household contact under treatment for TB. A clinical 
examination as well as an interview was performed 
with each community control to exclude any concom-
itant diseases including HIV, syphilis and other chronic 
illnesses as a part of the routine at the blood bank. In 
all study subjects the presence of a BCG scar and body 
mass index (BMI) were registered. The TST response 
was measured after blood was drawn for the analysis 
of QFN, CD4  cell count and HIV. CD4  cell counts 
were obtained using a FACSCount instrument (BD, 
San Jose, California, USA). The initial CD4  cell 
count was measured within 2 weeks of treatment ini-
tiation. All patients and study subjects were offered 
pre- and post-test counselling at the voluntary counsel-
ling and testing (VCT) clinic prior to HIV testing 
according to the hospital routine. HIV-positive patients 
were referred for treatment to the anti-retroviral ther-
apy (ART) clinic, available at the hospital. This study 
was conducted according to the principles expressed 
in the Declaration of Helsinki. The study was approved 
by the Research and Publication Offi ce of the Univer-
sity of Gondar, Gondar College of Medical and Health 
Sciences, Ethiopia and the Regional Ethics Review 
Board, Link ö ping, Sweden. All patients and study 
subjects were included only after obtaining written 
informed consent. 
 Clinical data 
 According to the TB score, signs and symptoms were 
recorded as previously described [12]. The presence or 
absence of clinical symptoms including cough, hae-
moptysis, dyspnoea, chest pain and night sweating 
were recorded, as well as clinical signs and other 
parameters including anaemia (paleness of the con-
junctivae at eye examination), tachycardia, lung aus-
cultation fi ndings, fever, BMI (  16 or   18 kg/m 2 ) and 
mid-upper arm circumference (MUAC   200 or 
 220 mm), resulting in a TB score from 0 to 13. By 
dividing the patients based on the initial score, patients 
were distributed into 3 severity classes (SC): SC-I, a TB 
score of 0 – 5; SC-II, a TB score of 6 – 7; and SC-III when 
the TB score was   8 points [12]. 
 HIV serology 
 The HIV status of the TB patients was analysed 
with Enzygnost Anti-HIV 1/2 Plus (Dade Behring, 
652  J. Idh et al. 
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y.Germany) and confi rmed with Vironistika HIV 
Uni-Form II Ag/Ab (Biom é rieux, France) using 
an enzyme-linked immunosorbent assay (ELISA) 
multi-well reader (Anthos Labtech instrument 2001, 
Austria). The blood donors were analysed accord-
ing to the hospital routines with the Vironistika HIV 
Uni-Form II Ag/Ab micro-ELISA system. 
 QuantiFERON  ®  -TB Gold In-Tube assay (QFN) 
 Blood samples were collected in tubes provided by 
the manufacturer of the QFN test (Cellestis). QFN 
is an in vitro diagnostic test that uses a peptide cock-
tail simulating ESAT-6, CFP-10 and TB7.7 (p4) pro-
teins to stimulate cells in heparinized whole blood. 
At inclusion, after 2 – 3 months and after 7 months of 
anti-TB treatment, a QFN test was done according to 
the manufacturer ’ s instructions (Cellestis). All QFN 
samples were collected in the morning at 09.00 a.m. – 
12.00 p.m. One millilitre of blood was collected into 
each of the 3 QFN blood collection tubes. At the time 
of sample collection and prior to incubation, the sam-
ples were mixed thoroughly by shaking the tube 10 
times (5 s) to ensure that the entire inner surface of 
the antigen coated tube was covered with the blood. 
The samples were transported and incubated at 37 ° C 
at 12.00 p.m. for 18 – 22 h after which the serum was 
frozen at   20 ° C for later analysis. 
 Tuberculin skin test (TST)
 Two tuberculin units of purifi ed protein derivative 
(PPD; Statens Serum Institute (SSI), Copenhagen, 
Denmark) were injected intradermally on the ventral 
aspect of the lower arm. The diameter of the skin 
induration was measured 48 – 72 h later according to 
the manufacturer ’ s instructions (SSI, Denmark). A 
diameter of   10 mm was considered positive.  Statistics 
 Data are presented as mean  standard deviation 
(SD). To compare groups, the Student ’ s  t -test was 
used for parametric data and the Chi-square test for 
discrete variables. A  p -value of   0.05 was considered 
statistically signifi cant. Kappa was calculated accord-
ing to Cohen. Signifi cant variables were entered into 
a multiple logistic regression model using the STA-
TISTICA software package (StatSoft, Tulsa, USA). 
 Results 
 Clinical data 
 Seventy-one sputum smear-positive TB patients were 
included in the study (Table I). Fifty-four percent 
( n   38, mean age 32  10 y) were HIV-positive (HIV-
positive/TB) and 46% ( n   33, mean age 25  6 y) 
were HIV-negative (HIV-negative/TB). A control group 
of blood donors ( n   41, mean age 27  8 y, all male) 
without a history of TB or any household contacts on 
TB treatment was recruited. Among HIV-negative/TB 
patients, 27/33 (82%) completed 8 months of treat-
ment, none died, 1 defaulted and 5 patients were trans-
ferred out. Among HIV-positive/TB patients, 27/38 
(71%) completed 8 months of treatment, 2 patients 
defaulted, 8 died and 1 was transferred out. The pres-
ence of a BCG scar was low in general (13% among 
HIV-negative/TB and 24% among HIV-positive/TB 
patients). No difference in the severity of clinical 
symptoms and signs measured as the TB score was 
found between HIV-positive/TB and HIV-negative/TB 
patients at inclusion. HIV-positive/TB patients had a 
signifi cantly lower CD4  cell count at inclusion com-
pared to HIV-negative/TB patients (219  154 vs 561 
 283 cells/µl,  p   0.01). Healthy blood donors had a 
signifi cantly higher CD4  cell count compared to 
HIV-negative/TB patients ( p   0.001, Table I).  Table I. Baseline characteristics of TB patients and community controls.  
Characteristic
HIV-neg/TB
 n   33
HIV-pos/TB
 n   38  p -Value
TB total
 n   71
Controls
 n   41
Age, y 25  6 32  10   0.01 28.8  9.1 27  8
Sex 15F, 18M 14F, 24M NS 29F, 42M 0F, 41M
Body mass index, kg/m 2 16.3  1.6 16.7  2.0 NS 16.5  1.9 20  2
TB score 7.6  2.3 7.4  2.1 NS 7.5  2.2 0.63  1.1
BCG scar 13.3% (4/30) 24.2% (8/33) NS 19.0% (12/63) 10.3% (4/39)
CD4  cell count (cells/µl) 561  283 219  154   0.01 375  280 786  218
TST (mm) 18  8 15  10 NS 16  9 7  8
TST   10 mm 87.9% (29/33) 73.0% (27/37) NS 80.0% (56/70) 47.2% (17/36)
QuantiFERON: positive 93.8% (30/32) 70.3% (26/37)   0.05 81.2% (56/69) 51.2% (21/41)
QuantiFERON: negative 6.2% (2/32) 27.0% (10/37)   0.05 17.4% (12/69) 43.9% (18/41)
QuantiFERON: indeterminate 0.0% (0/32) 2.7% (1/37) NS 1.4% (1/69) 4.9% (2/41)
Data are presented as mean  standard deviation.
HIV, human immunodefi ciency virus; TB, tuberculosis; M, male; F, female; BCG, bacille Calmette–Guérin; TST, tuberculin skin test; NS, 
not signifi cant.
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and TST 
 Defi ning a positive TST as   10 mm, 87.9% of HIV-
negative/TB patients and 73.0% of HIV-positive/TB 
patients had a positive TST when diagnosed with TB, 
compared to the QFN test where 93.8% of HIV-
negative/TB patients and 70.3% of HIV-positive/TB 
patients were positive, giving an overall sensitivity for 
smear-positive pulmonary TB (HIV-positive and 
HIV-negative/TB) of 80.0% for the TST and 81.2% 
for QFN including indeterminate results in the 
denominator (Table I). 
 A CD4  cell count   200 cells/µl signifi cantly 
affected the rate of patients positive in the TST (61.1% 
(11/18) with a CD4  cell count   200 cells/µl vs 
85.7% (42/49) with a CD4  cell count   200 cells/µl, 
 p   0.03), whereas QFN-positive patients exhibited a 
non-signifi cant difference (72.2% (13/18) with a 
CD4  cell count   200 cells/µl vs 91.5% (43/47) with 
a CD4  cell count    200 cells/µl,  p   0.10). The 
lowest CD4  count recorded was 30 cells/µl and this 
subject had a positive QFN test. A detailed presenta-
tion of QFN and TST results in relation to CD4  
counts is shown in Figure 1. 
 Concordance between TST and QFN 
 Agreement between the TST and QFN was poor in 
the TB patients (kappa 0.09) compared to the com-
munity controls (kappa 0.59). Three patients were 
negative in both QFN and TST (4.4%, 3/68), and 
25% of all TB patients (17/68) had discordant TST 
and QFN results (Table II). In a control group of 
blood donors with no history of TB and with no house-
hold contact on TB treatment, a positive TST was 
observed in 47% (17/36) and a positive QFN in 51% 
(21/41) (Table I). The number of indeterminate QFN 
results was 5.0% (12/240) overall, including the healthy 
blood donors at baseline, and varied between 2.7% 
and 10% during follow-up with 2.7% (3/110) at base-
line, 10% (5/49) at month 2 – 3 and 5.1% (2/39) at 
month 7). 
 Kinetics of QFN in relation to HIV co-infection 
 The rate of QFN-positive TB patients was signifi cantly 
reduced during treatment from baseline to 7 months 
(from 93.8% to 62.5% in HIV-negative/TB and from 
70.3% to 33.3% in HIV-positive/TB patients;  p   0.05, 
Table III). Following 2 – 3 months of anti-TB treatment, 
the rate of TB patients positive in the QFN decreased 
from 93.8% to 74% (17/23) in HIV-negative/TB 
and from 70.3% to 42% (11/26) in HIV-positive/TB
patients ( p   0.05), and after 7 months there was a 
signifi cant reduction to an overall QFN positivity 
of 51.3% (20/39,  p   0.05) compared to 81.2% at  inclusion (Table III). After 2 – 3 months of treatment 
5.3% (1/19) of HIV-negative/TB patients and 42.9% 
(9/21) of HIV-positive/TB patients ( p   0.01) who had 
a positive QFN result at inclusion had converted to a 
negative result, while 10.0% (4/40) converted from a 
positive to an indeterminate result. The rate of QFN-
positive individuals turning negative after 7 months 
of treatment was still higher among HIV-positive/TB 
than HIV-negative/TB patients (70%, 7/10 vs 29%, 
6/22,  p   0.05). Conversion from negative to positive 
QFN was observed in 2 of 5 HIV-positive/TB patients 
after 2 – 3 months of treatment. After completion of the 
intensive phase of TB treatment, 36.8% (14/38) of the 
HIV-positive/TB patients were initiated on ART against 
HIV, while the remaining patients were followed up at 
the ART clinic. The rate of patients on ART, positive 
in the QFN at month 7 was increased compared to co-
infected TB patients without ART (4/5 vs 3/9), however 
the number of patients in each group was very small. 
 QFN and TST results at diagnosis in relation to 
clinical outcome and initial severity of disease 
 Multiple logistic regression analysis showed a sig-
nifi cant correlation between a negative TST initially Figure 1. (a) TST (mm) and (b) QuantiFERON-TB Gold In-Tube 
(IU/ml IFN-γ) at inclusion in relation to CD4+ cell count (cells/
µl) for both HIV-positive (fi lled dots) and HIV-negative (unfi lled 
squares) tuberculosis patients. The cut-off values for a positive test 
for TST and QFN are indicated with the horizontal lines. Only 
patients for whom CD4+ cell counts and QFN (n = 65) or TST 
(n = 64) were available are plotted. The only indeterminate QFN 
result is plotted as an open circle (224 CD4+ cells/µl).
654  J. Idh et al. 
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(adjusted odds ratio 30.7; 95% confi dence interval 
1.52 – 618.2;  p   0.026), which was not confounded 
by factors such as HIV, age or sex. Moreover, TST-
negative patients had lower cure rates, higher mortal-
ity and an increased smear-positive rate at week 8 
compared to TST-positive patients, although this did 
not reach statistical signifi cance (Table III). There 
was no correlation between a negative QFN test and 
the severity of disease or the fi nal treatment outcome 
(Table III). 
 Discussion 
 We have investigated the kinetics of the QFN test in 
a high endemic area for TB and HIV, and the relation-
ship between QFN and TST and the severity of dis-
ease, as there is a lack of studies on these aspects. 
There are few, if any previous reports on the correla-
tion between QFN reactivity, TST and the clinical 
severity of disease, although it is well known that there 
are discrepancies between QFN and TST during 
active TB [12], which we could also confi rm. To study 
the clinical severity of TB, we used a previously vali-
dated scoring system for TB—the TB score [13]. We 
found that a negative TST correlated to a high initial 
TB score indicating more severe disease, which was 
not observed in QFN-negative individuals despite 
similar levels of CD4  cells. Importantly, this indi-
cates that the severity of the disease may not be an 
essential factor for a patient with active TB to test 
negative for QFN. Moreover, this observation further 
underlines the clinical differences between the tests 
during active TB and might refl ect that TST-responses 
are less sensitive than QFN in more advanced TB. We 
found no correlation between patients with a negative 
QFN and fi nal treatment outcome or sputum smear 
conversion, although a negative TST showed a ten-
dency to a poor clinical outcome (Table III). In con-
trast, Katiyar et al. [11] found in a study of 76 patients with active TB that an increased or persistent IFN- γ 
response at 2 months was associated with a 17.3 
( p   0.007) times higher likelihood of remaining 
culture-positive at 2 months. However, both studies 
are limited by the small sample size and a loss to 
follow-up of QFN. Taken together our data indicate 
that a negative TST is associated with a poor prog-
nosis and more severe disease, which is not the case 
with patients exhibiting a negative QFN test. 
 As one of the few published studies describing 
the kinetics of QFN results during treatment of active 
pulmonary TB in a high endemic area, we found a 
signifi cant decrease following 7 months of anti-TB 
treatment in HIV-negative/TB and HIV-positive/TB 
patients. These fi ndings are in agreement with those 
of Kobashi et al. [9] who found that the rate of QFN-
positive decreased from 83% ( n   40) at treatment 
initiation to 58% at treatment completion (6 months), 
and with Domínguez et al. [8] who found a sensitivity 
of 69% (25/36) for QFN in patients with pulmonary 
TB at treatment initiation compared to patients dur-
ing treatment, where 49% (21/43) were positive. Tran-
sient responses in serial testing with QFN have been 
reported such as a 33% (5/15) reversion and 6% 
(3/48) conversion after 3 months [14] and 22% (6/27) 
discordant result in healthcare workers after 3 days 
[15]. It has also been described that in patients with 
QFN levels in close relation to the cut-off (0.2 – 0.7 
IU/ml) the test is vulnerable to bias and reversions, 
which might not correlate to biological changes [16]. 
However, it is unlikely that transient responses have 
affected our results from the kinetic QFN investiga-
tion signifi cantly, as we studied active TB which had 
high QFN responses generally. Furthermore, the QFN 
results were stable during treatment at month 2 – 3 and 
month 7. It is more likely that the observed decrease 
is explained by the effect of anti-TB treatment by 
which the immune response to TB antigen is reduced 
and thereby altering an IFN- γ response below the 
threshold for a positive QFN reaction. On the other 
hand a conversion from negative to positive QFN dur-
ing anti-TB treatment can be a sign of a recovering 
immune response. In our study the rate of QFN-pos-
itive individuals turning negative was higher among 
HIV-positive/TB patients than HIV-negative/TB 
patients (month 2 – 3: 42.9% vs 5.3%, and month 7: 
70% vs 29%,  p   0.05). Conversion from negative to 
positive QFN was only observed in 2 of 5 HIV-posi-
tive/TB patients after 2 – 3 months of treatment. One 
reason could be that other aspects than the CD4  
T-cell count of host immunity are responsible for this 
effect, such as an increased turnover of T-cells or 
decreased functionality of this subset. Another factor 
that could affect the rate of QFN conversion following 
treatment is ART, but our study sample is too small 
to come to any conclusions in this regard (Table III).  Table II. Concordance between TST and QuantiFERON  ®  -TB 
Gold In-Tube results.  
TST QFN-pos QFN-neg
QFN 
indeterminate
HIV-neg/TB
 ( n   32)
Positive
Negative
27
3
1
1
0
0
HIV-pos/TB
 ( n   36)
Positive
Negative
20
6
7
2
0
1
CC Positive 13 3 1
 ( n   36) Negative 4 14 1
TST, tuberculin skin test; QFN, QuantiFERON-TB Gold In-
Tube; HIV, human immunodefi ciency virus; TB, tuberculosis; CC, 
community control.
Only cases with complete data available for both TST and QFN 
were included.
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infl uenced by the TST in a TST-positive population 
when a follow-up is performed 2 – 4 weeks later [17], 
as well as in serial testing a month after TST among 
healthy subjects with a TST   15 mm (15% 5/33) 
[18]; however if tested with QFN the day of TST and 
the day of TST reading there was no increase in the 
rate of positive QFN [19]. Nevertheless, the relative 
contribution of TST testing to boosting in patients 
diagnosed with clinical TB is likely to be minor and it 
is unlikely that boosting could be a major part of the 
explanation of persistent QFN positivity seen in HIV-
negative/TB patients in the present study. 
 The overall sensitivity of the IFN- γ release assay 
QFN was found to be 81.2% in our study population 
of 71 sputum smear-positive TB patients, which is 
similar to the TST using a cut-off for a positive test 
at   10 mm. Our data are comparable to previous 
published fi ndings from a high TB endemic area in 
Zambia (QFN positivity 74%, TST positivity 67%) [6] 
and from Tanzania (overall QFN positivity 74%, HIV-
negative/TB 81% and HIV-positive/TB 65%) [7]. 
 Although we did not detect a difference in the 
overall sensitivity between the TST and QFN, agree-
ment between the 2 methods was poor, which has 
been described previously [6]. Confi rming our data 
in the community controls, a previous study found 
fair agreement between the TST (5- and 10-mm 
cut-offs) and the QFN test (kappa   0.52 – 0.6) at 
least in HIV-positive/TB patients [3]. The TST test is 
based on the principle that latent or active TB induces 
a strong cell-mediated immune response that can be 
measured by the response to an intradermal inocula-
tion of tuberculin purifi ed protein derivative (PPD), 
a mixture of many M. tuberculosis proteins [1]. Dis-
cordant results between IGRAs and the TST cannot 
be completely explained by the notion that IGRAs 
are more specifi c with regard to cross-reaction with 
non-TB mycobacterial infections or with the BCG 
vaccine. Although the BCG vaccine coverage of com-
munity controls and TB patients in our study was low, 
there was no correlation between discordant results 
and the presence of a BCG scar (data not shown). 
 Estimations of sensitivity and specifi city for the 
QFN are problematic because of the lack of a gold 
standard for latent infection and because the test 
cannot separate active from latent disease. This is a 
particular concern in high endemic areas. Thus, our 
data from healthy blood donors without any signs of 
pulmonary TB confi rm several reports showing that 
latent infection measured as QFN reactivity is com-
mon (51% (21/41) in this study) in high endemic 
areas [3]. This underlines that although the QFN 
has a fairly high sensitivity, the clinical value for 
diagnosing smear-positive TB in a high endemic 
area is impaired by the low specifi city due to a high background of latent infection. An alternative, as 
proposed from a study with 216 students in India 
who underwent testing with TST and QFN, is to 
modify the optimal thresholds to distinguish infec-
tions from non-specifi c variations [20]. In low TB 
endemic areas like the Nordic countries, the back-
ground prevalence has been described in the range 
of 2% in HIV-negative and 4% in HIV-positive indi-
viduals [4], thus making QFN a more useful diag-
nostic tool for latent TB in these countries. 
 HIV co-infection has been described to have an 
infl uence on the QFN test, since IFN- γ production 
might be limited by the reduced number and func-
tion of CD4  T-cells [1]. Moreover, we observed 
reduced levels of CD4  T-cells on diagnosis also in 
HIV-negative/TB patients, which has been described 
previously. Low CD4  cell counts have been found 
to be associated with an increase in both indetermi-
nate and false-negative QFN results in some studies 
[6,21], but as has been noted in other studies [7], 
low CD4  T-cell counts do not seem to account for 
all indeterminate and negative results in HIV-posi-
tive/TB patients. In agreement with this observation 
we could not detect a signifi cant correlation in the 
HIV-positive/TB group between negative QFN 
results and low CD4  cell counts, including the rate 
in patients with CD4  cell counts lower than 200 
cells/µl. We found that even very low CD4  cell 
counts may result in an IFN- γ response high enough 
to be detected in the QFN test, suggesting that the 
quality and function of the present CD4  T-cells are 
of importance. Possibly, CD8  T-cells could contrib-
ute to the increased IFN- γ production in patients 
with low levels of CD4  T-cells. 
 We conclude that the QuantiFERON  ®  -TB Gold 
In-Tube reactivity is signifi cantly reduced at the end 
of treatment against active TB to the background 
level of healthy blood donors. In smear-positive TB 
patients, agreement between the TST and QFN is 
poor, including correlation to the severity of disease, 
which is most likely linked to the ability of the tests 
to measure different aspects of immunity. 
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